|
OTCMarketbulls.com Reports Hot Market Movers For December 30, 2009 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) +39.58%, Luna Innovations Incorporated (NASDAQ: LUNA) +26.97%, SKRM Interactive, Inc. (OTCBB: SECI) +67.86%,
(M2 PressWIRE Via Acquire Media NewsEdge) OTCMarketBulls is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring value to shareholders. Some of our past picks had soared as much as 4600%. To view some of our profiled stocks, please visit our website at http://www.otcmarketbulls.com/OTCMBlandingpage.php.
____________________________
CYCC LATEST NEWS
Cyclacel Announces Publication of Peer-Reviewed Journal Article Describing the Mechanism of Action of Seliciclib
Seliciclib's Down-Regulation of the Mcl-1 Protein Highlighted
BERKELEY HEIGHTS, N.J., Dec. 30, 2009 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of an article that reviews and discusses the company's seliciclib (CYC202 or R-roscovitine) product candidate, an orally available inhibitor of multiple cyclin-dependent kinases (CDKs) and its mechanism of action. The peer-reviewed article, "Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs" was published in the online edition of Current Drug Targets.
"The publication sets out the body of evidence that seliciclib is a promising anti-cancer agent that promotes cancer cell death by down-regulation of key proteins, such as p53 and Mcl-1, associated with survival of cancer cells," said Professor David Glover, Ph.D., Cyclacel's Chief Scientist. "A broader therapeutic role for CDK inhibitors in chronic proliferative diseases in addition to cancer has continued to emerge. Recently published evidence suggests that seliciclib promotes apoptosis of uncontrolled white blood cells, including neutrophils and eosinophils, also by down-regulation of Mcl-1. This is a novel finding with promising implications for the treatment of autoimmune and inflammatory conditions, including asthma. It builds upon previously published data showing seliciclib activity in lupus nephritis, polycystic kidney disease, pulmonary fibrosis and rheumatoid arthritis. We look forward to highlighting these non-oncology indications, unveiling Cyclacel's next-generation CDK inhibitors, and reviewing our promising pipeline programs at a Company-sponsored analyst day in 2010."
Poor therapeutic outcomes and serious side effects are common problems of current cancer therapies. Acquired drug resistance is a further major emerging problem as cancer cells learn to evade the activity of anti-cancer drugs by expressing proteins, such as Mcl-1, that make them immortal. The urgent need for new cancer-targeted drugs that can overcome resistance has led to the development of molecules that specifically inhibit CDKs.
The Current Drug Targets article reports the development of CDK inhibitors and their anti-cancer activities, with special attention to the mechanism of action of multi-kinase CDK inhibitors, including Cyclacel's seliciclib, currently in Phase 2 clinical trials as a treatment for various cancers. The ability of CDK inhibitors to suppress transcription and sensitize certain cancer cells to apoptosis by down-regulating the expression of the Mcl-1 protein and their synergy in combination with common DNA damaging anti-cancer drugs are also discussed. Citation: Krystof V, Uldrijan S., Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs, Curr Drug Targets. 2009 Dec 23. [Epub ahead of print].
Recently scientists from the Centre for Inflammation Research at the University of Edinburgh published preclinical evidence that seliciclib may be a promising treatment for asthma. They studied the effects of the drug on immune cells of the respiratory system known as eosinophils which help the body fight off infections. Uncontrolled proliferation of eosinophils can damage other cells that line lung tissues and thus contribute to inflammatory conditions such as asthma. Researchers found that exposure to seliciclib caused proliferating eosinophil cells to undergo apoptosis or programmed cell death by down-regulating the expression of the Mcl-1 protein. Citation: Duffin R, et al., The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1, FEBS Lett. 2009 Aug 6;583(15):2540-6.
About seliciclib
Seliciclib is an orally available molecule that selectively inhibits multiple CDK enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control. Seliciclib has been administered to approximately 450 patients in Phase 1 and Phase 2 trials. It is currently being evaluated in the APPRAISE trial, a Phase 2b randomized double-blinded study as a treatment in patients with non-small cell lung cancer (NSCLC) who failed at least two prior therapies and in a randomized Phase 2 study as a single agent in patients with nasopharyngeal cancer.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans to submit a Special Protocol Assessment (SPA) request for a pivotal study with sapacitabine during the first quarter of 2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid and Numoisyn(R) Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
____________________________
LUNA LATEST NEWS
Luna Strengthens its Position in Nanomedicine Tego Biosciences is acquired by Luna Innovations
ROANOKE, Va.--(12-29-09)--Luna Innovations Incorporated (NASDAQ: LUNA) has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials. Tego Biosciences, Inc. is a wholly owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR). This acquisition integrates the patent assets of the two leading companies and provides Luna a dominant intellectual property portfolio in carbon nanomaterial-based pharmaceuticals.
"We are pleased to add Tego's portfolio of intellectual property to enhance our exciting program in nanomedicines," stated Dr. Kent Murphy, Chairman and CEO of Luna Innovations. "The acquisition of Tego's fullerene assets for use in pharmaceuticals demonstrates Luna's continued commitment to novel therapeutics using carbon nanomaterials to treat a variety of inflammatory diseases that address significant markets such as arthritis, allergies and asthma. In addition, Luna's technology is being used to improve diagnostic imaging by developing agents targeted to reveal brain cancer and plaque on arterial walls."
With this acquisition, Luna's intellectual property portfolio for carbon nanomaterials now includes seven owned patents, 10 licensed patents and 44 U.S. and foreign applications. In addition, Luna acquired the research programs Tego has sponsored in radiation protection, anti-viral therapies and macular degeneration, the leading cause of blindness in the elderly. Luna also acquired Tego's license to The Bronx Project (TBP), a program for developing new medicines based on carbon nanomaterials for Parkinson's and other neurodegenerative diseases. As a result of this transaction, Luna and Tego will equally share in the net proceeds from activities related to the TBP license.
Luna has had an ongoing program to identify novel therapeutic candidates based on the unique properties of carbon nanospheres since 2003. These nanospheres, called buckminister fullerenes, must be chemically modified to make them compatible with living tissues. During this work, Luna has made a number of discoveries, funded in part by government contracts and awards. Luna's business strategy for developing pharmaceutical products is to form partnerships with established companies to underwrite the expensive development programs.
"Tego accrued the combined fruits of most of the pioneering research on fullerene therapeutics that have been discovered over the last decade. Combining these assets with our own discoveries provides Luna with extensive intellectual property covering therapeutics based on carbon nanomaterials," said Dr. Robert Lenk, President of Luna's nanoWorks Division based in Danville, VA. "Our combined patent portfolio consists of 61 patents and pending applications covering classes of fullerene derivatives, methods for synthesizing these compounds and treatments for specific diseases. This acquisition strengthens our position in carbon nanomaterial-based nanomedicines and opens additional markets to attract potential partners as we move forward."
About Luna Innovations & Luna nanoWorks:
Luna Innovations Incorporated (www.lunainnovations.com) develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Our products are used to measure, monitor, protect and improve critical processes in the markets we serve. nanoWorks (www.lunananoworks.com) is a division of Luna Innovations housed in a world-class nanomaterial manufacturing facility in Danville, VA, where scientists are developing pharmaceutical products empowered by nanomaterials with applications in diagnostics and therapeutics.
____________________________
SECI LATEST NEWS
Sector 10, Inc. CEO Message to Investors and Supporters
BELLEVUE, WA--(12/29/09) - Sector 10, Inc. (OTC.BB:SECI) (Frankfurt:4SR1)
A message from Sector 10, Inc. Company CEO Pericles DeAvila to Investors and Supporters:
I wanted to personally wish you a Happy New Year and a prosperous 2010. Sector 10, Inc. is looking forward to the year ahead and the impact our technology will have on the US market and globally. Our life saving technologies represent a parading shift for emergency response and will change the industry as it stands today. In their early stages, many new technologies face unexpected challenges during the process of introduction into new markets. In 2009, Sector 10, Inc. successfully dealt with many of these unexpected challenges which delayed the introduction of our services and products to market. With new capital and a clear path to execution, we are prepared to launch our products and technologies.
In 2010, we expect the PLX-3D system and our self-rescue devices will be adopted by several US cities as a tool that will allow responders, emergency personnel and facilities managers the ability to manage population, facilities and response systems during incidents or disaster of any magnitude from a mobile interface. The PLX-3D system is a bridging/integration platform that integrates Sector 10's pre-deployed self-rescue devises (MRU and SRUs), with the latest technology in personnel tracking, 3D video surveillance, full spectrum communications and a layered toolbox of interoperable accountability systems to save lives and coordinate response capabilities during times of incidental uncertainty. Sector 10's systems are fully self-sufficient and rely on a multitude of redundancy protocols to ensure their survivability during losses of power and legacy terrestrial communications.
Thank you for your past and continued support as we launch our products in 2010. We will continue to release news of our progress and achievements as they develop.
Happy New Year!
About Sector 10, Inc. (http://sect.qualitystocks.net)
Sector 10, Inc. is redefining the emergency response paradigm from centralized equipment staging to onsite pre-deployed resources. Sector 10 is the only emergency response systems company so strongly emphasizing pre-deployed resources as the way to save lives, avert injuries, reduce liability and to "Bridge the Survival Gap." http://www.sector10inc.com.
____________________________
OTCMarketbulls.com is an online financial destination where money managers, analysts, and individual investors can converge to discover new and exciting investment news, opportunities, and ideas. OTCMarketBulls.com is focused on finding emerging growth companies that do not necessarily have widespread analyst coverage on Wall Street. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTCMarketBulls.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
For full disclaimer/disclosure: http://www.otcmarketbulls.com/disclaimer.php
Visit Us On Twitter and Facebook: http://twitter.com/otcmarketbulls http://www.facebook.com/otcmarketbulls
SIGN UP FOR OUR FREE NEWSLETTER AND FREE EMAIL ALERTS!! http://www.otcmarketbulls.com/OTCMBlandingpage.php
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To Homepage ]
|
